Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management (TICA KOREA)

Seung-Jung Park

Status and phase

Completed

Phase 4

Conditions

Myocardial Ischemia

Acute Coronary Syndrome

Angina Pectoris

Cardiovascular Diseases

Heart Diseases

Treatments

Drug: Clopidogrel

Drug: Ticagrelor

Study type

Interventional

Funder types

Other

Identifiers

NCT02094963

AMCCV2013-14

Details and patient eligibility

About

The purpose of this study is to assess safety and efficacy of Ticagrelor versus Clopidogrel in Asian/KOREAn patients with acute coronary syndromes intended for invasive management.

Enrollment

800 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 and more
Index event of non-ST or ST segment elevation ACS
Provision of signed informed consent

Exclusion criteria

Hypersensitivity to aspirin or ticagrelor
Oral anticoagulation therapy that cannot be stopped
Treated with thrombolysis within 24hrs
Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
Any life-threatening condition with life expectancy less than 6months
Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
High risk due to malignant hypertension
The conditions associated with increased risk of bradycardiac events
Subjects with severe liver disease
Subjects requiring dialysis
Increased bleeding risk
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
Thrombocytopenia or leukopenia
Positive pregnancy test or is known to be pregnant